Molecular Pathology & Genomics
To be a world class division of LMP that provides department, collegiate and national leadership in the pursuit of excellence in molecular pathology and genomic research, education and clinical service
To foster a culture of innovation and academic excellence by promoting synergistic collaborations among members of the Division of Molecular Pathology and Genomics
Grand Rounds sponsored by the Division of Molecular Pathology and Genomics
April 11, 2018
- Understand the current use of human pluripotent stem cells for modeling metabolic disease;
- Apply modern gene editing techniques to understand the genetic causes of metabolic diseases
- Develop a strategy to identify novel therapeutics for metabolic disease
May 16, 2018
Lynn Bry, MD, PhD
Associate Pathologist, Brigham and Women’s Hospital
Associate Professor of Pathology
Harvard Medical School
Save the date!
The annual MPG Symposium will be held October 11, 2018 at Coffman Memorial Union with keynote speaker Dr. Muneesh Tewari from the University of Michigan. He will discuss the integration of cell free DNA with wearable sensors for early cancer diagnosis.
Tewari is Ray and Ruth Anderson-Laurence Sprague Memorial Research Professor, Professor of Internal Medicine, and Professor of Biomedical Engineering. He is also affiliated with the Department of Computational Medicine and Bioinformatics.
Recent MPG Faculty Publications
Yang R, Van Etten JL, Dehm SM. Indel detection from DNA and RNA sequencing data with transIndel. BMC Genomics. 2018 Apr 19;19(1):270. doi: 10.1186/s12864-018-4671-4.
Rashidi A, Nelson AC, Linden MA, Weisdorf DJ, Dolan MM, Ustun C. Genomics of clonal evolution in a case of essential thrombocythemia. Leuk Lymphoma. 2018 Feb;59(2):497-500. doi: 10.1080/10428194.2017.1337113. Epub 2017 Jun 11.
Pérez Ortiz JM, Orr HT. Spinocerebellar Ataxia Type 1: Molecular Mechanisms of Neurodegeneration and Preclinical Studies. Adv Exp Med Biol. 2018;1049:135-145. doi: 10.1007/978-3-319-71779-1_6.
Lou E, D'Souza D, Nelson AC. Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.J Natl Compr Canc Netw. 2017 Apr;15(4):427-432. PMID:28404754